Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

Нарлапревир

Эффективность и безопасность пероральной комбинированной терапии препаратами Нарлапревир/Ритонавир и Софосбувир у пациентов с хроническим гепатитом С (генотип 1), не получавших ранее лечение

Разрешение№ 55 от 02.02.2017
Номер протоколаCJ05013053
ФазаФаза II
Участников по плану125
Сроки02.02.2017 — 31.03.2021
РазработчикЗАО «Алмедис»
Страна разработчикаРоссия
Начало: 2 февраля 2017Окончание: 31 марта 2021
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/permit/ru/55/2017-02-02/

Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 125 чел. в стране «Россия».
  • Центров в реестре: 7 в 2 городах. Список — ниже на странице.
  • Плановая дата окончания (03.2021) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–70 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • Предшествующее лечениеранее не лечились (первая линия)
  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 42 · невключение: 15

Критерии включения

  • Are willing and able to provide written informed consent.
  • Have confirmed chronic HCV infection as documented by:
  • positive anti-HCV antibody (Ab) test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit
  • Have HCV genotype 1 at screening as determined by the Central Laboratory. Any nondefinitive results must exclude the subject from study participation.
  • Minimum HCV-RNA level of ≥ 10,000 IU at baseline;
  • Treatment-naive patients to be enrolled into 8 week cohort must have HCV-RNA level <1,000,000 IU/L at baseline;
  • No evidence of cirrhosis; availability at Baseline of at least one of the following tests negative results:
  • Liver biopsy within 2 years of screening showing absence of cirrhosis
  • Fibroscan® with a result of ≤ 12.5 kilopascal (kPa) within 6 months of baseline/Day1
  • FibroTest® score of ≤ 0.48 AND Aspartate aminotransferase (AST)-to-Platelet Ratio Index (APRI) of ≤ 1 performed during screening
  • In the absence of a definitive diagnosis of the presence or absence of cirrhosis by the above criteria, a liver biopsy was required. Liver biopsy results supersede the results obtained by Fibroscan® or FibroTest®
  • Have a screening electrocardiogram (ECG) without clinically significant abnormalities (P wave < 0.1 s; PQ interval 0,12-0,2 s; QRS complex 0,06-0,1 s; QT interval 0,35-0,49 s).
  • Must have the following laboratory parameters at screening:
  • alanine aminotransferase (ALT) ≤ 10 x the upper limit of normal (ULN)
  • AST ≤ 10 x ULN
  • Hemoglobin ≥ 12g/dL for male, ≥ 11g/dL for female subjects
  • Platelets ≥ 50,000cells/mm\^3 (for patients in 8-week study treatment group - ≥ 150,000 cells/mm3)
  • International normalized ratio (INR) ≤ 1.5 x ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR
  • Albumin ≥ 3 g/dL;
  • Direct bilirubin ≤ 1.5 x ULN;
  • Hemoglobin A1c (HbA1c) ≤10%;
  • Creatinine clearance (CLcr) ≥ 60 mL/min, as calculated by the Cockcroft-Gault equation.
  • Have not been treated with any investigational drug or device within 30 days of the screening visit.
  • A female subject is eligible to enter the study if it is confirmed that she is:
  • Not pregnant or nursing;
  • Of nonchildbearing potential (i.e., women who have had a hysterectomy, both ovaries removed, or medically documented ovarian failure, or are postmenopausal women >50 years of age with cessation \[for ≥ 12 months \] of previously occurring menses), or
  • Of childbearing potential (i.e., women who had not had a hysterectomy, both ovaries removed, or medically documented ovarian failure). Women ≤ 50 years of age with amenorrhea are considered to be of childbearing potential. These women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on the baseline/Day 1 visit prior to enrollment. They must also agree to one of the following from the screening until 6 months after last dose of the investigational drugs:
  • Complete abstinence from intercourse. Periodic abstinence from intercourse (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not permitted.
  • Consistent and correct use of 1 of the following methods of birth control listed below in addition to a male partner who correctly uses a condom from the date of screening until 6 months after the last dose of the investigational drugs. Women of childbearing potential must not rely on hormone-containing contraceptives as a form of birth control during the study. Female subjects using a hormone-containing contraceptive prior to screening must stop their contraceptive regimen use from the date of screening until 6 months after their last dose of investigational drugs.
  • intrauterine device (IUD) with a failure rate of < 1 %;
  • female barrier method: cervical cap or diaphragm with spermicidal agent
  • tubal sterilization
  • vasectomy in male partner
  • All male study participants must agree to consistently and correctly use a condom, while their female partner agrees to use either 1 of the nonhormonal methods of birth control listed above or a hormone-containing contraceptive listed below, from the date of screening until 6 months after their last dose of investigational drugs:
  • implants of levonorgestrel
  • injectable progesterone
  • oral contraceptives (either combined or progesterone only)
  • contraceptive vaginal ring
  • transdermal contraceptive patch
  • Male subjects must agree to refrain from sperm donation for at least 6 months after the last dose of investigational drugs.
  • Are in generally good health as determined by the investigator.
  • Are able to comply with the dosing instructions for study drug administration and are able to complete the study schedule of assessments.

Критерии невключения

  • Had prior exposure to Interferon (IFN), ribavirin (RBV), or other approved or experimental Direct-acting Antivirals (DAA) targeting the HCV.
  • Had prior exposure to amiodarone within 24 months before the screening
  • Are pregnant or nursing female or male with pregnant female partner.
  • Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, cholangitis).
  • Are infected with hepatitis B virus (HBV) or human immunodeficiency virus(HIV).
  • Have history of malignancy diagnosed or treated within 5 years; subjects under evaluation for malignancy are not eligible.
  • Have chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent > 10 mg/day).
  • Have clinically relevant drug or alcohol abuse within 12 months of screening. A positive drug screen must exclude subjects unless it can be explained by a prescribed medication; the diagnosis and prescription must be approved by the investigator.
  • Have excessive alcohol consumption, defined as more than 3 drinks on any single day and more than 7 drinks per week for females, and > than 4 drinks on any single day and more than 14 drinks per week for males.
  • Have history of solid organ transplantation.
  • Have history of clinically significant illness or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol by Investigators' opinion.
  • Have history of a gastrointestinal disorder (or postoperative condition) that can interfere with the absorption of the study drug.
  • Have history of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
  • Usage of any prohibited concomitant medications as described in the protocol (Appendix 1 - list of drugs with expected drug-drug interactions due to concomitant ritonavir usage)
  • Have known hypersensitivity to the study investigational medicinal product, the metabolites, or formulation excipients.

Источник: ClinicalTrials.gov, NCT04246723 · запись обновлена в реестре 31 октября 2022.

Дизайн и результаты

ДизайнНерандомизированное, открытое (без ослепления), одна группа; цель — лечение
Включено участников (факт, все страны)85
Результатыв реестре не опубликованы
Что измеряют — первичные конечные точки (1), вторичных — 5
  • The proportion of patients achieved Sustained Virologic Response (SVR12) in treatment-naïve patients cohort, received study therapy during 12 weeks. — Week 12 of follow-up period (SVR12) - week 24 of the study

Цель исследования

Multicenter, open-label, phase II safety and efficacy study of all-oral combination of narlaprevir/ritonavir and sofosbuvir in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1.

Области и заболевания

Где проходит

7 центров в 2 городах

Откуда эта информация

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.